Jump to content

-->
  • Log in with Facebook Log in with Twitter Log In with Google      Sign In   
  • Create Account
  • .org
  • Districts
  • Media
  • SupportUs
  • Collaborate
  • Contact
  • Search
  • Join


Adverts help to support the work of this non-profit organisation. To go ad-free join as a Member.


Photo

BioTime Inc.

Started by caliban , Mar 25 2011 01:11 AM
economics regenerative medicine stemells tissue engineering regmed

  • Please log in to reply
777 replies to this topic

#151 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 24 April 2012 - 12:07 AM

Keryx Announces Positive Top-Line Results from Phase 3 Study; Medgenics Files ...
BioMedReports (subscription) - 3 hours ago
By Staff and Wire Reports Below is a look at some of the headlines for companies that made news in the healthcare sector on April 23, 2012.

View the full article

#152 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 23 April 2012 - 07:30 PM

BioTime and its Subsidiary OrthoCyte Corporation Provides Update on ...
SunHerald.com - 8 hours ago
ALAMEDA, Calif. -- BioTime, Inc. (NYSE Amex: BTX) announced today that BioTime's CEO Michael West, Ph.D. will provide and update the development of OTX-CP07 by BioTime's subsidiary OrthoCyte Corporation at an investor meeting in New York City.

View the full article

#153 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 23 April 2012 - 07:34 PM

BioTime's Subsidiary LifeMap Sciences, Inc. Presents Update on Product Development
EON: Enhanced Online News (press release) - 11 hours ago
ALAMEDA, Calif.--(EON: Enhanced Online News)--BioTime, Inc. (NYSE Amex: BTX) announced today that David Warshawsky, Ph.D., CEO of BioTime's subsidiary LifeMap Sciences, Inc. will provide and update on product development at an investor meeting in New ...

View the full article

#154 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 23 April 2012 - 07:24 PM

BioTime Demonstrates Efficient Method for the Manufacture of Cartilage ...
EON: Enhanced Online News (press release) - 11 hours ago
ALAMEDA, Calif.--(EON: Enhanced Online News)--BioTime, Inc. (NYSE Amex: BTX) and its wholly owned subsidiary OrthoCyte Corporation reported today a means of manufacturing cartilage from human embryonic stem cells that is suited for industrial scale-up ...

View the full article

#155 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 23 April 2012 - 07:23 PM

BioTime's Subsidiary Cell Cure Neurosciences, Ltd. Provides Update on OpRegen ...
EON: Enhanced Online News (press release) - 11 hours ago
ALAMEDA, Calif.--(EON: Enhanced Online News)--BioTime, Inc. (NYSE Amex: BTX) announced today that Charles S. Irving, Ph.D., the CEO of BioTime's subsidiary Cell Cure Neurosciences, Ltd.

View the full article

#156 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 23 April 2012 - 06:41 PM

BioTime's Subsidiary OncoCyte Corporation Provides Update on PanC-DxTM, and ...
SunHerald.com - 12 hours ago
ALAMEDA, Calif. -- BioTime, Inc. (NYSE Amex: BTX) announced today that Joseph Wagner, Ph.D., the CEO of BioTime's subsidiary OncoCyte Corporation and Karen B. Chapman, Ph.

View the full article

#157 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 23 April 2012 - 06:41 PM

BioTime Provides Update on ReneviaTM Product Development
SunHerald.com - 12 hours ago
ALAMEDA, Calif. -- BioTime, Inc. (NYSE Amex:BTX) announced today that William Tew, Ph.D., BioTime's Chief Commercial Officer will provide an update on the development of Renevia TM (formerly known as HyStem®-Rx) at an investor meeting in New York City.

View the full article

#158 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 23 April 2012 - 07:23 PM

BioTime and its Subsidiary OrthoCyte Corporation Provides Update on ...
EON: Enhanced Online News (press release) - 15 hours ago
ALAMEDA, Calif.--(EON: Enhanced Online News)--BioTime, Inc. (NYSE Amex: BTX) announced today that BioTime's CEO Michael West, Ph.

View the full article

#159 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 23 April 2012 - 06:41 PM

BioTime's Subsidiary ReCyte Therapeutics, Inc. Provides Update On Preclinical ...
TheStreet.com (press release) - 15 hours ago
By Business Wire 04/23/12 - 02:32 PM EDT BioTime, Inc. (NYSE Amex: BTX) announced today that Steven Kessler, Ph.D., Vice President of Research at BioTime's subsidiary ReCyte Therapeutics, Inc. will provide and update on the development of reprogramming ...

View the full article

#160 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 23 April 2012 - 06:24 PM

BioTime's Subsidiary OncoCyte Corporation Provides Update on PanC-Dx™, and ...
MarketWatch (press release) - 16 hours ago
ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) -- BioTime, Inc. (ASE:BTX) announced today that Joseph Wagner, Ph.D., the CEO of BioTime's subsidiary OncoCyte Corporation and Karen B. Chapman, Ph.

View the full article

#161 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 23 April 2012 - 07:30 PM

BioTime's Subsidiary ReCyte Therapeutics, Inc. Provides Update on Preclinical ...
SunHerald.com - 18 hours ago
ALAMEDA, Calif. -- BioTime, Inc. (NYSE Amex: BTX) announced today that Steven Kessler, Ph.D., Vice President of Research at BioTime's subsidiary ReCyte Therapeutics, Inc. will provide and update on the development of reprogramming technologies and the ...

View the full article

#162 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 23 April 2012 - 07:23 PM

BioTime Provides Update on ReneviaTM Product Development
EON: Enhanced Online News (press release) - 18 hours ago
ALAMEDA, Calif.--(EON: Enhanced Online News)--BioTime, Inc. (NYSE Amex:BTX) announced today that William Tew, Ph.D., BioTime's Chief Commercial Officer will provide an update on the development of Renevia TM (formerly known as HyStem®-Rx) at an ...

View the full article

#163 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 23 April 2012 - 06:25 PM

BIOTIME, INC. : BioTime's Subsidiary OncoCyte Corporation Provides Update on ...
4-traders - 19 hours ago
BioTime, Inc. (NYSE Amex: BTX) announced today that Joseph Wagner, Ph.D., the CEO of BioTime's subsidiary OncoCyte Corporation and Karen B. Chapman, Ph.

View the full article

#164 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 23 April 2012 - 08:10 PM

BioTime's Subsidiary LifeMap Sciences, Inc. Presents Update on Product Development
Generation NT (US) - Apr 23, 2012
BioTime, Inc. (NYSE Amex: BTX) announced today that David Warshawsky, Ph.D., CEO of BioTime's subsidiary LifeMap Sciences, Inc. will provide and update on product development at an investor meeting in New York City today.

View the full article

#165 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 24 April 2012 - 06:37 PM

Keryx Announces Positive Top-Line Results from Phase 3 Study; Medgenics Files ...
Proactive Investors USA & Canada - Apr 24, 2012
Below is a look at some of the headlines for companies that made news in the healthcare sector on April 23, 2012. Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), announced its Japanese partner, Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co.

View the full article

#166 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 23 April 2012 - 06:37 PM

BioTime and its Subsidiary OrthoCyte Corporation Provides Update on ...
Benzinga - Apr 23, 2012
By Allie Wickman BioTime, Inc. (NYSE: BTX) announced today that BioTime's CEO Michael West, Ph.D. will provide and update the development of OTX-CP07 by BioTime's subsidiary OrthoCyte Corporation at an investor meeting in New York City.

View the full article

#167 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 23 April 2012 - 04:06 PM

Method to manufacture cartilage from human embryonic stem cells
News-Medical.net - Apr 23, 2012
BioTime, Inc. (NYSE Amex: BTX) and its wholly owned subsidiary OrthoCyte Corporation reported today a means of manufacturing cartilage from human embryonic stem cells that is suited for industrial scale-up of a product for the treatment of ...

View the full article

#168 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 18 April 2012 - 02:44 AM

Mesoblast hits 50% enrolment for back pain trial
Australian Life Scientist - Apr 18, 2012
Mesoblast (ASX:MSB) has enrolled half the patients for a US trial of off the shelf stem cells to restore degenerated intervertebral discs.

View the full article

#169 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 26 April 2012 - 01:37 PM

BioTime: Backed By Dubious Stock Promoters
Seeking Alpha - 1 hour ago
In our previous article, we discussed how BioTime, Inc. (BTX) has used press releases, particularly regarding the creation and acquisition of numerous subsidiaries, to boost the company's share price.

View the full article

#170 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 20 April 2012 - 05:04 PM

BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX, Inc.
BiotechStockTrader.com - Apr 20, 2012
BioTime, Inc. (BTX) and its wholly owned subsidiary LifeMap Sciences today announced that they have signed a definitive agreement to acquire XenneX, Inc. through a merger of XenneX into LifeMap Sciences.
BioTime Unit LifeMap Sciences To Buy Privately Held XenneX - Quick Facts - RTT News

View the full article

#171 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 02 May 2012 - 02:58 AM

Midday: Aus shares reverse gains

Midday: Aus shares reverse gains
Finance News Network - May 2, 2012
Buoyed by positive offshore leads, on the back of strong US and Chinese manufacturing data, the Australian share market rose at open but reversed gains and is trading flat noon.

View the full article

#172 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 02 May 2012 - 03:45 AM

Australian Stock Market Report – Midday 5/2/2012

Australian Stock Market Report – Midday 5/2/2012
International Business Times AU - May 2, 2012
By Vittorio Hernandez | May 2, 2012 1:43 PM EST The Australian share market improved for the second straight day yesterday, with the All Ordinaries Index (XAO) up 30 points to 4497 points.

View the full article

#173 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 05 September 2011 - 10:54 AM

Mesoblast Ltd Receives Clearance To Begin First European Trial Of Allogeneic Or 'Off-The-Shelf' Stem Cell Treatment For Heart Attacks


View the full article

#174 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 10 May 2012 - 02:23 AM

MESOBLAST LIMITED : MSB ASX NEW DIRECTOR - 10 MAY 2012

MESOBLAST LIMITED : MSB ASX NEW DIRECTOR - 10 MAY 2012
4-traders - May 10, 2012
NEW TEVA REPRESENTATIVE JOINS MESOBLAST BOARD OF DIRECTORS Melbourne, Australia; 10 May 2012: Global regenerative medicine company Mesoblast Limited (ASX: MSB) today announced the appointment of Dr Ben-Zion Weiner, Special Adviser to the CEO of Teva ...
Teva Representative Joins Mesoblast's Board of Directors - BiotechStockTrader.com

View the full article

#175 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 22 August 2011 - 11:00 AM

First Minimally-Invasive Procedure Performed In Mesoblast Ltd's Phase 2 Stem Cell Trial For Lumbar Disc Repair


View the full article

#176 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 26 September 2011 - 10:35 PM

Mesoblast Ltd Enters Into Strategic Alliance With Lonza Group Ltd


View the full article

#177 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 23 August 2011 - 11:58 PM

Mesoblast Ltd Not To Pay FY 2011 Final Dividend

Mesoblast Ltd Not To Pay FY 2011 Final Dividend
Reuters Key Development - Aug 23, 2011

View the full article

#178 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 07 July 2011 - 10:45 AM

Mesoblast Ltd Receives FDA Clearance For Phase 3 Bone Marrow Transplant Trial


View the full article

#179 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 10 May 2012 - 10:02 AM

New Teva Representative Joins Mesoblast Board of Directors

New Teva Representative Joins Mesoblast Board of Directors
MarketWatch (press release) - May 10, 2012
MELBOURNE, Australia, May 10, 2012 /PRNewswire via COMTEX/ -- Global regenerative medicine company Mesoblast Limited (asx:MSB) today announced the appointment of Dr Ben-Zion Weiner, Special Adviser to the CEO of Teva Pharmaceutical Industries Ltd, ...

View the full article

#180 ImmInst

ImmInst

    robot

  • Admin, Director
  • 2,350 posts
  • 72 ₮

Posted 21 May 2012 - 04:48 PM

XenneX completes merger with LifeMap Sciences
Mass High Tech - May 21, 2012
By Lori Valigra BioTime Inc. (NYSE: BTX) and its subsidiary LifeMap Sciences Inc., both of Alameda, Calif., on May 18 completed the acquisition of XenneX Inc. of Cambridge through a merger of XenneX into LifeMap, according to a filing with the US ...

View the full article
Back to Ventures & Markets



Also tagged with one or more of these keywords: economics, regenerative medicine, stemells, tissue engineering, regmed

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users

  1. LONGECITY
  2. → Round Table Discussion
  3. → Business
  4. → Ventures & Markets
  5. Forum Rules